Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 3 for:    Cellect

ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04006652
Recruitment Status : Not yet recruiting
First Posted : July 5, 2019
Last Update Posted : March 12, 2020
Sponsor:
Collaborator:
Cellect Biotechnology
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
Finding a donor remains a challenge for patients in need of an urgent hematopoietic stem cell transplantation (HSCT). The ability to obtain half matched stem cells from any family member represents a significant breakthrough in the field. Haploidentical haplo-HSCT is characterized by the nearly uniform and immediate availability of a donor and the availability of the donor for post-transplant cellular immunotherapy. However, haplo-HSCT has a high risk of Graft versus Host Disease (GvHD) and poor immune reconstitution when GvHD is prevented by all existing methods of vigorous ex vivo or in vivo T-cell depletion. Different treatment approaches are currently being explored to mitigate complications such as graft rejection, severe GvHD, and prolonged immune suppression. Novel experimental utilization of T regulatory cells, alloreactive natural killer (NK) cells, and other T cell subsets hold great promise. Cellect Biotherapeutics' platform technology, ApoGraft, is based on the findings that GvHD can be prevented by Fas receptor mediated selective depletion of T cell subsets, ex vivo. The investigators hypothesize that the use of ApoGrafts for haplo-HSCT will be safe, and reduce rates of GVHD without affecting Graft-versus-Leukemia (GvL).

Condition or disease Intervention/treatment Phase
Acute Graft Versus Host Disease Haploidentical Hematopoietic Stem Cell Transplant Drug: ApoGraft Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The first three recipients will be treated in a sequential manner meaning that subjects will be transplanted with ApoGraft only after the engraftment of the previous subject has occurred.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients
Estimated Study Start Date : April 30, 2020
Estimated Primary Completion Date : April 30, 2023
Estimated Study Completion Date : April 30, 2023


Arm Intervention/treatment
Experimental: Recipient
  • Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy which will be administered at the discretion of the treating physician
  • Recipients will undergo a single fresh ApoGraft transplant as per standard clinical site guidelines
Drug: ApoGraft
ApoGraft is a cell based product, manufactured with mobilized peripheral blood.

No Intervention: Donor
-Donors will undergo apheresis from peripheral blood after daily G-CSF administration (for up to 5 days prior to Day -1)



Primary Outcome Measures :
  1. Safety and tolerability of ApoGraft as measured by adverse events related to ApoGraft product [ Time Frame: From day 0 to 1 year post-transplantation of ApoGraft product ]
    -The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for all toxicity reporting.


Secondary Outcome Measures :
  1. Cumulative incidence of graft failure [ Time Frame: 35 days post haplo-HCT ]
    -Failure to engraft will be defined as failure to achieve absolute neutrophil count > 500 for 3 days by Day 35

  2. Treatment related mortality [ Time Frame: Through 1 year post-transplantation of ApoGraft product ]
    -Death that results from a transplant procedure-related complication (e.g. infection, organ failure, hemorrhage, GVHD) rather than from relapse of the underlying disease or an unrelated cause.

  3. Time of neutrophil engraftment as determined by number of days for reaching first of 3 consecutive days with ANC ≥ 500/mm3 [ Time Frame: 35 days post haplo-HCT ]
  4. Rate of neutrophil engraftment as determined by number of days for reaching first of 3 consecutive days with ANC ≥ 500/mm3 [ Time Frame: 35 days post haplo-HCT ]
  5. Time of platelet engraftment determined by number of days for reaching first of 3 consecutive days with platelets ≥ 20,000/mm3 in the absence of platelet administration during the prior 7 days [ Time Frame: 35 days post haplo-HCT ]
  6. Rate of platelet engraftment determined by number of days for reaching first of 3 consecutive days with platelets ≥ 20,000/mm3 in the absence of platelet administration during the prior 7 days [ Time Frame: 35 days post haplo-HCT ]
  7. Incidence of Grade 2-4 acute GVHD [ Time Frame: Day 180 ]
    -Acute GVHD will be assessed using MAGIC criteria

  8. Time to development of Grade 2-4 acute GVHD [ Time Frame: Day 180 ]
    -Acute GVHD will be assessed using MAGIC criteria

  9. Incidence of Grade 3-4 acute GVHD [ Time Frame: Day 180 ]
    -Acute GVHD will be assessed using MAGIC criteria

  10. Time to development of Grade 3-4 acute GVHD [ Time Frame: Day 180 ]
    -Acute GVHD will be assessed using MAGIC criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Recipient Inclusion Criteria:

  • Adult male or female subjects, 18-70 years of age.
  • Availability of an HLA-haploidentical-HSCT related donor with a minimum match of 5/10 at the HLA A, B, C, DR and DQ loci.
  • Hematologic malignancy in remission or controlled as below:

    • Acute myelogenous leukemia (AML) and Acute lymphoblastic leukemia (ALL) in 1st or subsequent complete remission (CR)
    • Non-Hodgkin's Lymphoma (NHL) in CR by CT or PET/CT
    • Hodgkin's disease (HD) in 1st or subsequent CR by CT or PET/CT
    • Intermediate or high risk Myelodysplastic syndrome (MDS) (IPSS-R criteria)
  • ECOG performance status score 0-1 at time of the screening visit
  • Cardiac left ventricular ejection fraction ≥ 40% in adults within 4 weeks of Day 0.
  • Pulmonary function test with DLCO, FEV1 and FVC of ≥ 50% within 4 weeks of Day 0.
  • Oxygen saturation ≥ 90% on room air at screening visit.
  • Subjects must have adequate organ function as defined below within 2 weeks of Day 0:

    • AST (SGOT)/ALT (SGPT) ≤ 2.5 × upper limit of normal (ULN).
    • Serum bilirubin <3 mg/dL.
    • Estimated creatinine clearance >50
  • If female of childbearing potential, agree to use an acceptable method of birth control or be surgically sterile, and have a negative pregnancy test.
  • Available HLA-haploidentical donor
  • Must be able to receive GvHD prophylaxis with tacrolimus, mycophenolate mofetil, and cyclophosphamide
  • Able to understand and willing to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). Subjects requiring a guardian to sign informed consent will not be included.

Recipient Exclusion Criteria:

  • If a matched related donor is available and able to donate
  • Participation in an interventional investigational trial within 30 days of the screening visit
  • Subject suffering from any active or ongoing malignancy (other than the reason for HSCT) in the last 5 years prior to baseline; excluding basal cell carcinoma, in situ malignancy, low-risk prostate cancer, cervix cancer after curative therapy.
  • Uncontrolled infections (bacterial, viral or fungal including sepsis, pneumonia with hypoxemia, persistent bacteremia, or meningitis within two weeks of the screening visit).
  • Current known active acute or chronic infection with HBV or HCV.
  • Known human immunodeficiency virus (HIV) infection or AIDS.
  • Subjects with severe or symptomatic restrictive or obstructive lung disease or respiratory failure requiring ventilator support.
  • Subjects with other concurrent severe and/or uncontrolled medical condition, which could compromise participation in the study (i.e. active infection, uncontrolled diabetes, uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, and chronic liver or renal disease)
  • History of any of the following within 12 months prior to screening: Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), unstable angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism.
  • Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder or any chronic condition susceptible, in the opinion of the investigator, of interfering with the conduct of the study.
  • Organ allograft transplant recipient.
  • If female of childbearing potential, agree to use an acceptable method of birth control or be surgically sterile, and have a negative pregnancy test.
  • Pregnancy or lactation
  • Must not have undergone a prior allogeneic donor (related, unrelated, or cord) transplant. Prior autologous transplant is not exclusionary.
  • Presence of donor-specific anti-HLA antibodies.
  • Must not receive antithymocyte globulin as part of pre-transplant conditioning regimen, plan to receive a T-cell depleted product, or have planned donor leukocyte infusions post-transplant.
  • Immunosuppressive doses of steroids. Subjects with steroids for adrenal insufficiency will not be excluded.

Donor Inclusion Criteria

  • Adult male or female subjects, 18-65 years of age.
  • Donor criteria according to standard NMDP criteria for donor selection.

    • Blood-related family member (sibling (full or half), offspring, parent, cousin, niece or nephew, aunt or uncle, or grandparent).
    • HLA-haploidentical donor/recipient match by at least low-resolution typing per institutional standards.
    • In the investigator's opinion, donor is in general good health, and medically able to tolerate leukapheresis required for harvesting HSC.
  • Fit to receive G-CSF and donate peripheral blood stem cells.
  • Able to sign written informed consent including consent for 2nd donation in the event of graft failure in the recipient.

Donor Exclusion Criteria

  • HIV, HBV or HCV positive subjects within 30 days prior to day 0.
  • Pregnant or lactating women.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Graft donation with less than 0.3% CD34+ cells

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04006652


Contacts
Layout table for location contacts
Contact: Zhifu Xiang, M.D. 314-454-8304 zxiang@wustl.edu

Locations
Layout table for location information
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
Contact: Zhifu Xiang, M.D.    314-454-8304    zxiang@wustl.edu   
Principal Investigator: Zhifu Xiang, M.D.         
Sub-Investigator: Mark A Schroeder, M.D.         
Sub-Investigator: John F DiPersio, M.D., Ph.D.         
Sub-Investigator: Peter Westervelt, M.D., Ph.D.         
Sub-Investigator: Camille Abboud, M.D.         
Sub-Investigator: Amanda Cashen, M.D.         
Sub-Investigator: Keith Stockerl-Goldstein, M.D.         
Sub-Investigator: Ravi Vij, M.D.         
Sub-Investigator: Geoffrey Uy, M.D.         
Sub-Investigator: Mathew Walter, M.D.         
Sub-Investigator: Todd Fehniger, M.D., Ph.D.         
Sub-Investigator: Armin Ghobadi, M.D.         
Sub-Investigator: Meagan Jacoby, M.D., Ph.D.         
Sub-Investigator: Iskra Pusic, M.D.         
Sub-Investigator: Lukas Wartman, M.D.         
Sub-Investigator: John Welch, M.D., Ph.D.         
Sub-Investigator: Francesa Ferraro, M.D.         
Sub-Investigator: Matthew Christopher, M.D., Ph.D.         
Sponsors and Collaborators
Washington University School of Medicine
Cellect Biotechnology
Investigators
Layout table for investigator information
Principal Investigator: Zhifu Xiang, M.D. Washington University School of Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT04006652    
Other Study ID Numbers: 201911131
First Posted: July 5, 2019    Key Record Dates
Last Update Posted: March 12, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases